Performance-Enhancing Drugs : Understanding the Risks - 01/11/14
Résumé |
To help clinicians understand the risks associated with performance-enhancing drugs, this overview covers prohibited lists of substances and methods, therapeutic use exemptions, the legitimate indications and adverse effects, including for megadose and polypharmacy doping of stimulants, anabolic steroids, erythropoiesis-stimulating agents, and growth hormone and ways in which physicians or patients risk committing anti-doping rule violations inadvertently.
Le texte complet de cet article est disponible en PDF.Keywords : Anabolic steroids, Blood doping, Dietary supplements, Growth hormone, Nonanalytical positive doping cases, Sports doping, Stimulants, Therapeutic use exemptions
Plan
Disclosure Statement: C.K. Hatton and G.A. Green have received payments from Major League Baseball for consultation on anti-doping matters. P.J. Ambrose has received payments from the National Center for Drug Free Sport for drug-testing collections. |
Vol 25 - N° 4
P. 897-913 - novembre 2014 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?